Redbiotec develops prophylactic vaccines, with a strong focus on HCMV (human cytomegalovirus).

Expansion: pure HCMV VLPs
(April 2014)

Redbiotec has successfully assembled constructs leading to reVLPs® based on capsid and surface proteins from human cytomegalovirus (HCMV) only. Analyses including mass spectrometry and electron microscopy confirmed the presence of up to 11 HCMV proteins and showed the expected virus-like particles, further expanding Redbiotec’s leading programme of CMV vaccines.

Tackling Herpesviruses: data library

After Redbiotec’s achievements with the CMV vaccine development and based on the assembly power of its rePAX® platform, the company embarked on the creation of a Herpesvirus data library over the next years.
Redbiotec is convinced that this library will lead to the generation and optimization of Herpes vaccine candidates, and will eventually reveal potential causes of virus latency and help elucidate virus-triggered cancer mechanisms.


Duke Researcher Sallie Permar, MD PhD, joins Redbiotec’s Scientific Advisory Board
Schlieren, 21 July 2014
Redbiotec announces today the appointment of Dr. Sallie Permar, MD PhD, Associate Professor of Pediatrics at Duke University School of Medicine, to Redbiotec’s Scientific Advisory Board.
Dr. Permar is a leading scientist studying neonatal viral pathogenesis including congenital Cytomegalovirus (CMV) infection. Dr. Permar and her team utilize nonhuman primate models and human cohort studies to understand and elicit immune responses that can prevent vertical virus transmission.
Redbiotec’s team has the goal to develop the first CMV vaccine on the market and we are glad that Dr. Permar will scientifically support Redbiotec in its efforts.
Successful in vivo results
Schlieren, 11 July 2014
Redbiotec is pleased to announce that it has further validated its complex CMV antigens in two new in vivo (mouse) studies. One performed in house, one by a pharma partner. Redbiotec’s complex CMV antigens showed high neutralizing antibody titers even at low dose, both as standalone product as well as in a formulation combined with another CMV glycoprotein. For further information please do not hesitate to contact
Further news